Todd C Crawford1, Peter J Leary2, Charles D Fraser1, Alejandro Suarez-Pierre1, J Trent Magruder1, William A Baumgartner1, Kenton J Zehr1, Glenn J Whitman1, S Carolina Masri2, Farooq Sheikh3, Teresa De Marco4, Bradley A Maron5, Kavita Sharma6, Nisha A Gilotra6, Stuart D Russell7, Brian A Houston8, Bhavadharini Ramu8, Ryan J Tedford9. 1. Division of Cardiac Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington Medicine, Seattle, WA. 3. Advanced Heart Failure program, Mechanical Circulatory Support, and Cardiac Transplantation, MedStar Washington Hospital Center, Washington, DC. 4. Division of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, CA. 5. Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Cardiology, Boston VA Health Care System, Boston, MA. 6. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 7. Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC. 8. Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC. 9. Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC. Electronic address: TedfordR@musc.edu.
Abstract
BACKGROUND: At the recent 6th World Symposium on Pulmonary Hypertension (PH), the definition of PH was redefined to include lower pulmonary artery pressures in the setting of elevated pulmonary vascular resistance (PVR). However, the relevance of this change to subjects with PH due to left-heart disease as well as the preoperative assessment of heart transplant (HT) recipients is unknown. METHODS: The United Network for Organ Sharing database was queried to identify adult recipients who underwent primary HT from 1996 to 2015. Recipients were subdivided into those with mean pulmonary artery pressure (mPAP) < 25 mm Hg and ≥ 25 mm Hg. Exploratory univariable analysis was undertaken to identify candidate risk factors associated with 30-day and 1-year survival (conditional on 30-day survival) in recipients with mPAP < 25 mm Hg, and subsequently, parsimonious multivariable Cox proportional hazards models were constructed to assess the independent association with PVR. RESULTS: Over the study period, 32,465 patients underwent HT, including 12,257 (38%) with mPAP < 25 mm Hg. The median age was 55 years (interquartile range, 47-62) and the median PVR was 1.5 Wood units (WU) (interquartile range, 1-2.2) in recipients with mPAP < 25 mm Hg. After controlling for confounders, PVR was independently associated with increased risk for 30-day mortality (hazard ratio, 1.16; 95% CI, 1.05-1.27; P < .01), but not conditional 1-year mortality (hazard ratio, 1.03; 95% CI, 0.94-1.12; P = .55). PVR ≥ 3 WU was associated with an absolute 1.9% increase in 30-day mortality in those with mPAP < 25 mm Hg, a similar risk to recipients with PVR ≥ 3 WU and mPAP ≥ 25 mm Hg. CONCLUSIONS: Elevated PVR remains associated with a significant increase in the hazard for 30-day mortality after cardiac transplantation, even in the setting of lower pulmonary artery pressures. These data support the validity of the new definition of pulmonary hypertension.
BACKGROUND: At the recent 6th World Symposium on Pulmonary Hypertension (PH), the definition of PH was redefined to include lower pulmonary artery pressures in the setting of elevated pulmonary vascular resistance (PVR). However, the relevance of this change to subjects with PH due to left-heart disease as well as the preoperative assessment of heart transplant (HT) recipients is unknown. METHODS: The United Network for Organ Sharing database was queried to identify adult recipients who underwent primary HT from 1996 to 2015. Recipients were subdivided into those with mean pulmonary artery pressure (mPAP) < 25 mm Hg and ≥ 25 mm Hg. Exploratory univariable analysis was undertaken to identify candidate risk factors associated with 30-day and 1-year survival (conditional on 30-day survival) in recipients with mPAP < 25 mm Hg, and subsequently, parsimonious multivariable Cox proportional hazards models were constructed to assess the independent association with PVR. RESULTS: Over the study period, 32,465 patients underwent HT, including 12,257 (38%) with mPAP < 25 mm Hg. The median age was 55 years (interquartile range, 47-62) and the median PVR was 1.5 Wood units (WU) (interquartile range, 1-2.2) in recipients with mPAP < 25 mm Hg. After controlling for confounders, PVR was independently associated with increased risk for 30-day mortality (hazard ratio, 1.16; 95% CI, 1.05-1.27; P < .01), but not conditional 1-year mortality (hazard ratio, 1.03; 95% CI, 0.94-1.12; P = .55). PVR ≥ 3 WU was associated with an absolute 1.9% increase in 30-day mortality in those with mPAP < 25 mm Hg, a similar risk to recipients with PVR ≥ 3 WU and mPAP ≥ 25 mm Hg. CONCLUSIONS: Elevated PVR remains associated with a significant increase in the hazard for 30-day mortality after cardiac transplantation, even in the setting of lower pulmonary artery pressures. These data support the validity of the new definition of pulmonary hypertension.
Authors: Bradley A Maron; Gabor Kovacs; Anjali Vaidya; Deepak L Bhatt; Rick A Nishimura; Susanna Mak; Marco Guazzi; Ryan J Tedford Journal: J Am Coll Cardiol Date: 2020-12-01 Impact factor: 24.094
Authors: Barry J Maron; Martin S Maron; Mathew S Maurer; Ethan J Rowin; Bradley A Maron; Nazzareno Galiè Journal: J Am Heart Assoc Date: 2021-10-08 Impact factor: 5.501
Authors: Avishay Grupper; Israel Mazin; Kobi Faierstein; Adam Kurnick; Elad Maor; Dan Elian; Israel M Barbash; Victor Guetta; Ehud Regev; Avi Morgan; Amit Segev; Jacob Lavee; Paul Fefer Journal: Front Cardiovasc Med Date: 2022-04-26
Authors: Agnieszka Dyla; Wojciech Mielnicki; Jacek Waszak; Hubert Szurmiak; Krystian Jakimowicz; Roch Pakuła; Michał Oskar Zembala Journal: Int J Environ Res Public Health Date: 2022-09-26 Impact factor: 4.614